Pathobiology of chemotherapy-induced hair loss.
Paus, R. Haslam, I.S. Sharov, A.A. Botchkarev, Vladimir A.
Paus, R.
Haslam, I.S.
Sharov, A.A.
Botchkarev, Vladimir A.
Publication Date
2013
End of Embargo
Supervisor
Keywords
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Hair loss can be a psychologically devastating adverse effect of chemotherapy, but satisfactory management strategies for chemotherapy-induced alopecia remain elusive. In this Review we focus on the complex pathobiology of this side-effect. We discuss the clinical features and current management approaches, then draw upon evidence from mouse models and human hair-follicle organ-culture studies to explore the main pathobiology principles and explain why chemotherapy-induced alopecia is so challenging to manage. P53-dependent apoptosis of hair-matrix keratinocytes and chemotherapy-induced hair-cycle abnormalities, driven by the dystrophic anagen or dystrophic catagen pathway, play important parts in the degree of hair-follicle damage, alopecia phenotype, and hair-regrowth pattern. Additionally, the degree of hair-follicle stem-cell damage determines whether chemotherapy-induced alopecia is reversible. We highlight the need for carefully designed preclinical research models to generate novel, clinically relevant pointers to how this condition may be overcome.
Version
No full-text in the repository
Citation
Paus R, Haslam IS, Sharov AA and Botchkarev VA. (2013) Pathobiology of chemotherapy-induced hair loss. Lancet Oncology, 14 (2): e50-9.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article